Reduction of MDR1, MRP1 and BCRP expression in Crohn’s disease: a role in disease pathogenesis? by Ana Savić Mlakar et al.
PERIODICUM BIOLOGORUM UDC 57:61 
VOL. 117, No 3, 347–355, 2015 CODEN PDBIAD 
DOI: 10.18054/pb.2015.117.3.3152 ISSN 0031-5362
original research article
 
Reduction of MDR1, MRP1 and BCRP expression  
in Crohn’s disease: a role in disease pathogenesis?
Abstract
Background and purpose: ABC transporters have a non-redundant 
role in the maintenance of gut homeostasis and changes in their expression 
may contribute to the Crohn’s disease pathology. As they are closely regu-
lated by the inflammatory milieu, the coexpression of ABC transporters, 
relevant proinflammatory cytokines and their negative regulators in the 
affected tissues could provide an insight to the pathological pattern of Crohn’s 
disease related to different disease phases.
Materials and Methods: Crohn’s disease patients were divided into 
three groups: newly diagnosed (untreated), active disease on therapy (treated) 
and remission. Intestinal mucosa from terminal ileum to rectum was com-
pared to matching mucosa from healthy controls for mRNA expression of 
MDR1, MRP1 and BCRP1. Affected terminal ileum and unaffected sig-
moid colon mucosa were compared to controls for mRNA expression of rel-
evant cytokines and suppressor of cytokine signaling molecules.
Results: MDR1 mRNA expression is downregulated in inflamed tissues 
irrespective of patient groups. MRP1 expression is reduced in the untreated 
group and normalized after therapy introduction. Inflamed ileum was char-
acterized by transitory increase in IFN-g, IL-17A and SOCS3 expression 
in the treated group. In the unaffected colon, no significant difference in the 
expression of the tested transporters was observed, even though IFN-g, IL-2 
and IL-1b expression was increased.  
Conclusion: Reduced MDR1 expression, irrespective of the disease 
group, and reduced MRP1 expression in untreated group, implicates the 
involvement of these transporters in the disease pathogenesis. The affected 
ileum lacks increased cytokine expression, while unaffected colon mucosa 
shows a Th1 cytokine profile.
IntroductIon
Crohn’s disease (CD) is a chronic intestinal bowel disorder (IBD) of unknown cause in which genetic and environmental factors, pri-
marily microbial, influence the gastrointestinal tract’s ability to balance 
pro- and anti-inflammatory mechanisms. The immunopathology is 
driven by innate cytokines like TNF-a, IL-6 and IL-1b that are respon-
sible for the chemokine release and neutrophil infiltration. Their produc-
tion is elevated in CD and they contribute to tissue damage directly or 
indirectly through elevation of matrix metalloproteinases (1–3). Pres-
ence of elevated expression and production of cytokines like IFN-g and 
IL-17, produced by CD4 Th1 and Th17 effector T cells, implicate an 
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The data on the possible involvement of ATP Binding 
Cassette (ABC) transporters in the pathogenesis of 
Crohn’s disease is inconclusive. Human gastrointestinal 
tract is continuously exposed to food antigens, commen-
sal or pathogenic microbiota, all of which are kept in tight 
balance and interaction. Disruption of this balance ulti-
mately leads to inflammation, as seen in IBD (6). ABC 
transporters form a part of the detoxification pathways, 
and are crucial in the maintenance of gut homeostasis and 
protection of epithelial cells from xenobiotics (7), and 
hence have a serious impact on the absorption and distri-
bution of orally administered drugs (8). The ABC trans-
porters MDR1 (P-glycoprotein, MDR1, encoded ABCB1) 
and BCRP (Breast Cancer Resistance Protein, encoded 
ABCG2) are apical side localized transporters with a pri-
mary role in the efflux of potentially harmful xenobiotics 
from intestinal epithelial cells. MDR1 expression along 
human intestine is highest in the terminal ileum with 
lower and continuous levels throughout colon (9). Similar 
pattern of expression is observed for BCRP, with the high-
est expression in the terminal ileum, a continuous de-
crease along the colon, and 50% reduction at the sigmoid 
colon (10). However, MDR1 and BCRP expression is 
reduced in inflamed tissues of CD patients (11). MDR1 
mRNA expression in inflamed tissue seems to be nega-
tively regulated by the proinflammatory cytokines (11), 
which could also be the case for BCRP (12). The decrease 
in ABC transporter expression could have a direct impli-
cation on the disease pathology, as mdr1a-/- mice develop 
spontaneous intestinal inflammation triggered by the 
normal bacterial flora that resembles human IBD (13). 
Moreover, double knock-out mdr1-/- and tlr2-/- mice de-
velop extensive colitis due to inefficient control of the non-
pathogenic bacteria, confirming a protective function of 
MDR1 in antibacterial defense (14, 15). Studies on ge-
netic polymorphisms of MDR1 in humans also implicate 
its involvement in the IBD pathogenesis (16).
The MRP1 (Multidrug resistance protein 1, encoded 
ABCC1) is a basolateral multifunctional transporter. Vari-
eties of different substrates of MRP1 have been determined 
showing preferential transport of amphiphilic anions, al-
though conjugation with glutathione and sulfate increases 
substrate compatibility (17, 18). MRP1 transports endog-
enously produced compounds as well, bioactive lipids be-
ing one of the more intriguing ones. Additionally, it is es-
sential for transport of leukotrienes, for example leukotriene 
C4 (LTC4), which is important pro-inflammatory lipid 
mediator implicated in IBD pathology (19). Besides its 
function in the transport of different toxic substrates, 
MRP1 transports reduced glutathione (GSH) and its oxi-
dized derivates like glutathione disulfide (GSSG), S-ni-
trosoglutathione (GS-NO) and glutathione-metal com-
plexes (20, 21). GSH represents the most important 
detoxifying and anti-oxidative intestine pathway. Blockade 
of GSH synthesis causes massive degeneration of epithe-
lial cells in the small intestine and colon (22). As MRP1 
can regulate levels of GSH and oxidized GSH derivates 
(23), it is also involved in direct control of redox homeo-
stasis and prevention of apoptosis of intestinal epithelial 
cells (24). MRP1 is equally expressed in all intestinal re-
gions (25), and its expression in IBD seems to be upregu-
lated (24). Recent findings suggest that mrp1-/- mice 
treated with DSS develop more severe colitis due to exten-
sive epithelial damage (26).
The first line treatment of CD includes drugs that are 
substrates of ABC transporters – for example glucocorti-
coids, which are effluxed by MDR1 (27), and sulfasalazine, 
effluxed by BCRP (28). Overexpression or increased activ-
ity of these transporters could have an impact on the ther-
apy outcome, as is the case of steroid resistance in IBD (29). 
In this study we aimed to determine the mRNA expres-
sion of MDR1, MRP1 and BCRP in the terminal ileum 
and colon of CD patients (untreated, treated and remission) 
and healthy controls. In addition, the expression of IFN-g, 
IL-2, IL-6, IL-1b and IL-17A, as well as two suppressors of 
cytokine signaling molecules (SOCS1 and SOCS3) were 
determined in the inflamed terminal ileum and sigmoid 
colon, as an increase in number and diameter of lymphoid 
aggregates in unaffected colonic tissues from CD patients 
has been observed (30, 31). Changes in the expression of 
cytokines and SOCS molecules at different stages of the 
disease could provide further information on disease patho-
genesis. Additionally, knowing the exact expression profiles 
of ABC transporters in human gastrointestinal tract could 
be useful in CD therapy design.
Methods
Patients and samples
Punch biopsy specimens from six different locations 
(terminal ileum, ascending colon, transverse c., descend-
ing c., sigmoid c. and rectum) were taken from 25 CD 
(average age 43.46±13.77) patients during routine colo-
noscopy. The diagnosis was based on classic clinical fea-
tures, as well as endoscopic, pathohistological and labora-
tory findings. Patients were divided into three groups 
based on the disease status:newly diagnosed (untreated), 
patients with active inflammation under therapy (treated) 
and patients in remission. Control samples were taken 
from non-IBD patients who undertook colonoscopy for 
clinical investigation of rectal bleeding, anaemia or func-
tional disorders like Irritable Bowel Syndrome (IBS) 
(n=10; average age 57.86±17.4). The expression of cyto-
kines and SOCS molecules were determined at inflamed 
terminal ileum and unaffected sigmoid colon. Control 
biopsies were compared to patient’s biopsies from the same 
site. Patient’s characteristics are presented in Table 1. The 
informed consent was obtained from all participants 
prior to inclusion and the protocol was approved by the 
Ethics Committees of University hospitals “Sisters of 
Charity” and “Dubrava”, Zagreb, Croatia. Samples were 
immediately immerged into a tube with RNAlater solu-
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tion (Ambion, Foster City, United States) for the preserva-
tion of the RNA and left overnight at +4oC so that the 
solution could uniformly penetrate the tissue. Supernatant 
was removed and samples were stored at –80oC until fur-
ther processing.
rnA isolation
Samples from each intestinal region were homogenised 
in RLT buffer for 20–30 seconds (T25basic, IKA 
Labortechnik, Germany) and total cellular RNA was iso-
lated using RNeasy Kit (Qiagen, Hilden, Germany) fol-
lowing protocol provided by the manufacturer. The pu-
rity and concentration of extracted total RNA was 
determined with Bio Photometer (Eppendorf, Hamburg, 
Germany) at A260/280.
reverse transcription
2ug of total RNA was reverse-transcribed using High 
Capacity cDNA Reverse Transcription Kit with RNAse 
inhibitor (Applied Biosystems, Foster City, United States) 
using protocol provided by the manufacturer, with ran-
dom hexamers as primers. The conditions of reverse tran-
scription reaction were: 25 ºC/10 min, 37 ºC/120 min, 
85 ºC/5 min, 4 ºC/∞. cDNA was stored at –200C until 
further processing.
taqMan analysis
Quantitative PCR of samples was performed on 7500 
Real-Time PCR System (Applied Biosystems) under follow-
ing thermal cycling conditions: 95 ºC/10 min, 40 cycles 95 
ºC/15s, 60 ºC/1 min. TaqMan Gene Expression Master 
Mix and TaqMan Gene Expression Assays for examined 
genes (MDR1 Hs00184491_m1, MRP1 Hs00219905_
m1, BCRP Hs00184797_m1, IFN-g Hs00989291_m1, 
IL-2 Hs01555413_m1, IL-6 Hs00985641_m1, IL-1b 
Hs00174383_m1, IL-17 Hs00174114_m1, SOCS1 
Hs00705164_s1 and SOCS3 Hs02330328_s1) were used 
following manufacturer’s protocol. GAPDH (Applied Bio-
systems) served as endogenous control. Samples were run 
in triplicates and no template control (NTC) was used as 
negative control for each gene. Data were collected and 
analysed with the 7500 System SDS Software.
Statistics: Data were analysed using the comparative 
Ct method (the ΔΔCt method) and the results are pre-
sented as transcript levels relative to levels in controls. 
After assessment of data normality by Shapiro-Wilk W 
test, and subsequent logarithmic transformation of non-
normally distributed variables, the expression of exam-
ined molecules in each segment of the intestine of CD 
patients were compared with that of control subjects by a 
multivariable regression analysis. Age, sex and concomi-
tant treatment of CD patients were considered as poten-
tial confounding factors. The Kendall-tau correlation 
coefficient was calculated to analyse the correlation be-
tween mRNA expression of ABC transporters and that 
of examined cytokines and SOCS molecules. All statisti-
cal analyses were performed using STATA 13.0 (Stata-
Corp. 2013. Stata Statistical Software: Release 13. College 
Station, TX: StataCorp LP).
Table 1. Patients characteristics
Controls (N=10) CD (untreated) (N=8) CD (treated) (N=9) CD (remission) (N=8)
Gender
Female 1 4 3 3
Male 9 4 6 5
Mean age, yr. ± SD 57.86 ± 17.4 41.38 ± 11.46 40.22 ± 13.78 46.88 ± 16.87
Extend of disease
CD
Ileal – 8 9 8
Ileocolic – – – –
Colon – – – –
Therapy
5-aminosalicylates – – 7 6
Corticosteroids – – 5 3
Immunesuppressives – – 4 3
Biologicals – – – –
None 10 8 – –
Pathological severity (CDAI)
remission – – – 8
mild – – – –
moderate – 7 7 –
severe – 1 2 –
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Figure 1. Transporter expression in CD pa-
tients at inflamed terminal ileum. The ex-
pression values of MDR1, MRP1 and BCRP are 
normalized to the housekeeping gene GAPDH 
and are presented relative to the matched loca-
tions of the controls. Data are presented as mean 
± SEM and statistically significant differences are 
indicated by *p <0,05, ** p<0,01 and ***p < 
0,001. Black bars = N group (untreated); dark 
grey = A group (treated); light grey = R group 
(remission); open bars = controls.
Figure 2. Transporter expression in CD pa-
tients at unaffected colon. The expression val-
ues of MDR1, MRP1 and BCRP are normalized 
to the housekeeping gene GAPDH and are pre-
sented relative to the matched locations of the 
controls. Data are presented as mean ± SEM. 
Black bars = N group (untreated); dark grey = A 
group (treated); light grey = R group (remission); 
open bars = controls.
results
expression of ABc transporters
MDR1 and BCRP mRNA expression along the exam-
ined intestinal locations in patients and healthy controls 
exhibits the same pattern, showing the highest expression 
at terminal ileum compared to the colon and rectum. 
There is also no difference in MRP1 mRNA expression 
pattern between patients and healthy controls or along 
intestine (data not shown).
A statistical analysis shows that in the inflamed ileum 
the mRNA expression of MDR1 was reduced in CD pa-
tients, by 56%, 72% and 58% in untreated, treated and 
remission group, when compared to healthy controls (Fig-
ure 1A). Neither the therapeutical intervention nor the 
achievement of the disease remission altered the down-
regulated MDR1 mRNA expression in ileum tissue from 
CD patients.
The MRP1 mRNA expression was reduced by 54% in 
ileum tissues of untreated CD patients compared to 
healthy controls. Introduction of a therapy increased 
MRP1 mRNA to healthy levels that sustained into the 
remission phase (Figure 1B). The reduction of BCRP 
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Figure 3. Cytokine and SOCS expression in the inflamed ileum of CD patients. The expression values of IFN-g, IL-2, IL-6, IL-1b, IL-
17A, SOCS1 and SOCS3 are normalized to the housekeeping gene GAPDH and are presented relative to the matched locations of the controls. 
Data are presented as mean ± SEM and statistically significant differences are indicated by *p < 0,05. Black bars = N group (untreated); dark 
grey = A group (treated); light grey = R group (remission); open bars = controls.
mRNA expression in untreated patients was borderline 
significant (p=0,070), while in treated group was reduced 
by 41% (Figure 1C). In remission the mRNA BCRP lev-
els were within range of healthy controls. 
Also, there were only minor differences in the expres-
sion levels of all three transporters throughout the unaf-
fected colon between CD patients and healthy controls.
expression of cytokines and socs 
molecules
At the inflamed terminal ileum of untreated CD pa-
tients, no significant difference in analysed cytokines or 
SOCS mRNA levels were detected (Figure 3A-G). Treat-
ment transiently increased IFN-g, IL-17A and SOCS3 
mRNA expression (7-fold, 3.5-fold and 5-fold, respec-
tively) when compared to healthy subjects and patients in 
remission. There were no significant differences for 
mRNA expression levels of IL-6, IL-1b and SOCS1 be-
tween defined CD groups and healthy subjects.
In contrast to inflamed terminal ileum, the levels of 
IFN-g, IL-2 and IL-1b mRNA at the unaffected sigmoid 
colon tissue were higher in untreated patients, with clear 
decrease on therapy introduction to the levels of healthy 
controls (Figure 4A-B,D). 
In the remission group of patients, the levels of IFN-g 
and IL-2 mRNA were higher again, while IL-1b mRNA 
remained at low levels. The expression of IL-17A at the 
unaffected colon was also elevated but reached a statistical 
significance only in the remission group (3.4-fold higher 
expression) (Figure 4E). Like in the inflamed ileum, there 
were no differences in IL-6 expression among the defined 
groups at unaffected colon (Figure 4C). The levels of 
SOCS1 and SOC3 mRNA at the unaffected sigmoid co-
lon tissue of CD patients followed the same pattern as 
found for IFN-g and IL-2 being higher in untreated pa-
tients, decreased in treated group and increased in remis-
sion, respectively (Figure 4.). In comparison to affected 
ileum, mRNA levels of SOCS1 were significantly higher 
in unaffected colon tissue.
dIscussIon
Efflux transporters contribute to the maintenance of 
gut homeostasis and hence to the intact gut barrier. Their 
role in the pathogenesis of IBD is controversial and to date 
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only a few studies examined the expression profiles of 
multiple efflux transporters simultaneously. Zimmerman 
et al. determined MDR1 and MRP1-5 transporter expres-
sion from duodenum to sigmoid colon and provided im-
portant data on site-specific expression, but the samples 
were taken only from healthy subjects (9). 
In the present study, we determined the expression 
profiles of MDR1, MRP1 and BCRP from terminal ile-
um to rectum in three groups of patients, each corre-
sponding to different disease phase, and matched tissue 
from healthy controls. The pattern of expression of all 
three transporters, with the highest expression at terminal 
ileum for MDR1 and BCRP, and constant expression for 
MRP1 along intestine, are similar between healthy and 
diseased subjects.
The expression level of MDR1 in CD patients is gener-
ally reduced, regardless of the disease phase. This overall 
reduction seems to be characteristic only for the inflamed 
ileum, since there were no differences in MDR1 expres-
sion along the unaffected colon. Functional consequence 
of downregulated MDR1 on IBD pathology was con-
firmed by Panwala et al. in a study using mdr1a-/- mice 
that developed spontaneous intestinal inflammation (13). 
This indicates that a loss of the efflux capacities of the gut 
may promote the development of colitis. However, it has 
been shown that MDR1 interferes with bacterial adhesion 
to enterocytes and reduces the risk of gastrointestinal dis-
orders (15). Interestingly, at the same time, mdr1a-/- mice 
display reduced expression of regenerating islet-derived 
protein 3 gamma (REG3G) in intestinal mucosa (32). 
REG3G prevents exaggerated inflammation by bacteri-
cidal activity and suppression of cytokine production (33). 
The interplay of MDR1 and REG3G in the balance of 
intestinal homeostasis is still unknown, but both are 
regulated by microbial colonization (34). Downregulated 
MDR1 expression in the ileum is in conflict with in-
creased REG3G expression in CD patients by Gironella 
et all (33) and assume different regulatory mechanisms. 
The observed overall reduction in MDR1 expression 
makes it a possible candidate in the CD pathogenesis and 
points to a certain physiological role, possibly through 
modulation of interactions with commensals and antimi-
crobials.
The expression of BCRP in the inflamed tissue is sim-
ilar to MDR1, with reduced expression during treatment, 
although the reduction in its expression in untreated CD 
group was borderline significant (p=0.070). This might 
be explained by the fact that suphasalazine and metho-
Figure 4. Cytokine and SOCS expression in the unaffected colon of CD patients. The  expression  values  of  IFN-g,  IL-2,  IL-6,  IL-1b, 
IL-17A,  SOCS1  and  SOCS3  are normalized to the housekeeping gene GAPDH and are presented relative to the matched locations of the 
controls. Data are presented as mean ± SEM and statistically significant differences are indicated by *p < 0,05. Black bars = N group (un-
treated); dark grey = A group (treated); light grey = R group (remission); open bars = controls.
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trexate, the common therapeutics for IBD, are known to 
raise homocysteine levels and lower folate levels, which 
ultimately results in the downregulation of BCRP expres-
sion (35). With the resolution of inflammation, the BRCP 
expression normalized to control values. Furthermore, we 
have found that patients treated with aminosalicylates 
had considerably lower expression of MDR1 (p=0.008) 
and BCRP (p=0.045). It is known that BCRP and MRP1 
are responsible for the efflux of glutathione (GSH) and its 
conjugated forms (36) and thus participate in the main-
tenance of intracellular redox status. Our results have 
shown that MRP1 expression was reduced in untreated 
CD group and normalized after resolution of inflamma-
tion. The reduced expression of MRP1, as well as BCRP, 
in ileal tissues of CD patients might affect efflux of ROS 
outside epithelial cells, rendering them more sensitive to 
apoptosis by Fas ligand and LTC4 (24, 37). Furthermore, 
Hove et al (26) shows that mrp1-/- mice treated with DSS 
develop more severe disease caused by severe epithelial 
damage, confirming a MRP1 role in IBD pathogenesis.
Several studies on various animal models showed that 
ongoing inflammatory responses have an impact on 
MDR1 and BCRP mRNA expression and function (38), 
which was also found to be true in humans (11). We have 
now found that the inflamed ileum of CD patients did 
not show the expected cytokine profile with elevated ex-
pression of IFN-g in the affected ileal tissue. However, we 
have found increased IFN-g expression in the treated 
group, which might have resulted from sulphasalazine 
treatment that can up-regulate the expression of IFN-g 
(39). Furthermore, there was no difference in IL-6 or IL-
1b expression among the defined groups, although IL-6 
was borderline significantly elevated in the untreated 
group (p=0.0625). Unexpectedly, the treatment tran-
siently increased IL-17A mRNA levels in the remission 
group. IL-17A has been linked to the pathology of CD, 
intensifying the potent mechanisms of innate immunity 
(40). It is regulated by IL-23, but the same cytokine is 
required for induction of counteractive IL-22, which has 
a protective role in CD (41), However, we did not measure 
IL-22 expression in order to determine the IL-17A/IL-22 
ratio. It is possible that the obvious lack of elevated expres-
sion of examined cytokines in inflamed tissue of CD pa-
tients can be explained by the presence of elevated expres-
sion of other inflammatory cytokines that were not 
included in the study, particularly TNF-a, which is 
known to be elevated and a target of successful anti-TNF-
a therapy (42). Lack of increased IL-1b and IL-17A levels 
is in line with ineffectiveness of anti-cytokines monoclo-
nal antibody treatments in CD (43, 44).
As SOCS molecules provide crucial negative feedback 
on the cytokine signaling, they might play a relevant role 
in the control of mucosal damage in IBD patients (45). 
Our results show that, in the inflamed tissue, there were 
no differences in SOCS1 expression between the defined 
groups. It is known that SOCS1 negatively regulates 
STAT1 pathway in the murine IBD model (46). Further-
more, SOCS1 is regulator of TNF-a and the lack of its 
elevated expression in the inflamed CD ileum might fur-
ther contribute to ongoing TNF-a mediated inflamma-
tion. On the other hand, an increase of SOCS3 mRNA 
levels in inflamed tissues of treated patients follows kinet-
ics of IFN-g and IL-17A expression. Higher levels of 
SOCS3 expression have been detected in the colon of IBD 
patients (47) and might be a result of the feed-back regu-
lation of STAT3 activation. SOCS3 has been proposed to 
balance between mucosal wound healing and hyperplasia 
(48) and a higher SOCS3 expression at the remission 
could predict mucosal relapse (49). 
In contrast to the inflamed ileum, increased IFN-g and 
IL-2 mRNA expression levels was detected in the unaf-
fected colon of the untreated group. Their expression nor-
malized to healthy levels in the treated group, but re-
gained upregulated expression in remission. IL-1b levels 
were also elevated in the untreated group, but normalized 
to control values after resolution of inflammation. This 
data demonstrate that the unaffected sigmoid colon in 
CD patients is characterized by the Th1 cytokine profile 
and elevated innate IL-1b expression, as is commonly ob-
served for CD. Interestingly, higher expression values of 
both SOCS1 and SOCS3 were found in the unaffected 
colon of CD patients which were accompanied by in-
creased IFN-g, IL-2, and IL-1b expression. High SOCS1 
and SOCS3 expression in the unaffected areas of the un-
treated group could be the reason why the unaffected 
areas do not display histological alternations in spite of 
the higher cytokine expression. Overall, our results indi-
cate that unaffected gastrointestinal tract tissue of CD 
patients differs from that of healthy controls. Our finding 
of deregulated cytokine production, together with the 
Nascimbeni et al. observation of formation of lymphoid 
aggregates in unaffected tissues, address a possible impor-
tant role in the disease pathology (50). In the present 
study we show general reduction in MDR1 expression in 
CD. Involvement of MRP1 in CD pathogenesis is plau-
sible, but further research is needed. Furthermore, our 
results demonstrate a lack of the expected Th1 cytokine 
profile in the inflamed tissue of CD patients. In contrast, 
the unaffected colon was characterized by increased ex-
pressions of the cytokines and SOCS molecules. The po-
tential functional importance of altered transporter ex-
pression in disease progression and the involvement of 
therapy should be further explored. 
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